TG02 (Zotiraciclib), a novel pyrimidine-based multi-kinase inhibitor, can inhibit ERK5 activity, leading to cell cycle arrest in multiple myeloma cells, thereby impeding proliferation and promoting apoptosis [198]. This evidence concerns the gene MAPK7 and plasma cell myeloma.